The efficacy of febuxostat 10 mg for the prevention of hyperuricemia associated with tumor lysis syndrome (TLS) in Japanese patients with non-Hodgkin's lymphoma

被引：4

作者：

Yasu, Takeo ^{[1
]}

Kobayashi, Shunsuke ^{[1
]}

Horii, Mai ^{[1
]}

Kurokawa, Yosuke ^{[1
]}

机构：

[1] Univ Tokyo, Inst Med Sci, Res Hosp, Dept Pharm, Tokyo, Japan

来源：

INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS | 2016年 / 54卷 / 12期

关键词：

tumor lysis syndrome; febuxostat; hyperuricemia; renal function; non-Hodgkin's lymphoma; PHASE-III; ALLOPURINOL; ADULTS; RISK; MALIGNANCIES; CHILDREN;

D O I：

10.5414/CP202635

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Tumor lysis syndrome (TLS) is a life-threatening oncologic emergency. The control of serum uric acid level (UA) is important for prevention of TLS. Febuxostat has demonstrated its superiority over allopurinol in decreasing UA level. We retrospectively evaluated the efficacy of febuxostat 10 mg in prevention of hyperuricemia associated with TLS (HU-TLS) in 12 patients with non-Hodgkin's lymphoma (NHL). Mean UA levels were found to significantly decrease (p = 0.003). HU-TLS was prevented in all patients. Thus, febuxostat 10 mg is effective in prevention of HU-TLS. Future study is need to deteimine whether the incidence of HU-TLS change with dosage of febuxostat.

引用

页码：1009 / 1011

页数：3

共 8 条

[1] Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus [J].

Cairo, Mitchell S. ;

Coiffier, Bertrand ;

Reiter, Alfred ;

Younes, Anas .

BRITISH JOURNAL OF HAEMATOLOGY, 2010, 149 (04) :578-586

[2] Control of Plasma Uric Acid in Adults at Risk for Tumor Lysis Syndrome: Efficacy and Safety of Rasburicase Alone and Rasburicase Followed by Allopurinol Compared With Allopurinol Alone-Results of a Multicenter Phase III Study [J].

Cortes, Jorge ;

Moore, Joseph O. ;

Maziarz, Richard T. ;

Wetzler, Meir ;

Craig, Michael ;

Matous, Jeffrey ;

Luger, Selina ;

Dey, Bimalangshu R. ;

Schiller, Gary J. ;

Pham, Dat ;

Abboud, Camille N. ;

Krishnamurthy, Muthuswamy ;

Brown, Archie, Jr. ;

Laadem, Abderrahmane ;

Seiter, Karen .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (27) :4207-4213

[3] Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index [J].

Goto, H ;

Tsurumi, H ;

Takemura, M ;

Ino-Shimomura, Y ;

Kasahara, S ;

Sawada, M ;

Yamada, T ;

Hara, T ;

Fukuno, K ;

Goto, N ;

Okuno, M ;

Takami, T ;

Seishima, M ;

Moriwaki, H .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2005, 131 (02) :73-79

[4] Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology [J].

Jones, Gail L. ;

Will, Andrew ;

Jackson, Graham H. ;

Webb, Nicholas J. A. ;

Rule, Simon .

BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 (05) :661-671

[5] Investigation of the freely available easy-to-use software 'EZR' for medical statistics [J].

Kanda, Y. .

BONE MARROW TRANSPLANTATION, 2013, 48 (03) :452-458

[6]

Lustberg ME, 2006, NEW ENGL J MED, V354, P1532

[7] An Allopurinol-Controlled, Multicenter, Randomized, Open-Label, Parallel Between-Group, Comparative Study of Febuxostat (TMX-67), a Non-Purine-Selective Inhibitor of Xanthine Oxidase, in Patients With Hyperuricemia Including Those With Gout in Japan [J].

Naoyuki, Kamatani ;

Shin, Fujimori ;

Toshikazu, Hada ;

Tatsuo, Hosoya ;

Kenjiro, Kohri ;

Toshitaka, Nakamura ;

Takanori, Ueda ;

Tetsuya, Yamamoto ;

Hisashi, Yamanaka ;

Yuji, Matsuzawa .

JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2011, 17 (04) :S44-S49

[8] FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk [J].

Spina, M. ;

Nagy, Z. ;

Ribera, J. M. ;

Federico, M. ;

Aurer, I. ;

Jordan, K. ;

Borsaru, G. ;

Pristupa, A. S. ;

Bosi, A. ;

Grosicki, S. ;

Glushko, N. L. ;

Ristic, D. ;

Jakucs, J. ;

Montesinos, P. ;

Mayer, J. ;

Rego, E. M. ;

Baldini, S. ;

Scartoni, S. ;

Capriati, A. ;

Maggi, C. A. ;

Simonelli, C. .

ANNALS OF ONCOLOGY, 2015, 26 (10) :2155-2161

← 1 →